This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Trius Therapeutics Presents Clinical Data On Experimental Antibiotic Tedizolid At ECCMID Meeting

SAN DIEGO and BERLIN, April 29, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery and development of antibiotics for serious infections, announced a range of clinical data for the experimental antibiotic tedizolid phosphate (TR-701) and a presentation on linezolid (Zyvox®)-resistant strain of bacteria. This took place at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting in Berlin.

In addition to the detailed efficacy and safety results of the ESTABLISH-2 study, which build upon the top-line results previously announced, Trius presented the results of a drug interaction clinical study demonstrating that tedizolid phosphate does not increase blood pressure when used in conjunction with vasoconstrictor drugs such as decongestants. In addition, the results of a separate clinical cardiovascular safety study showed that tedizolid is not associated with heart beat abnormalities at up to six times its effective dose, the maximum dose examined in the study. The results of both studies further support the safety profile for tedizolid. In addition, in an oral presentation, Trius provided an overview of data on an emerging class of bacterial pathogens that is resistant to linezolid (Zyvox), the only marketed drug of the same class as tedizolid. To date, these strains have proven susceptible to tedizolid. 

"There has been a significant need for new antibiotic therapies targeting resistant bacterial infections, such as MRSA," said Jeffrey Stein, Ph.D., CEO and President of Trius Therapeutics. "We are very excited to share these results, which build upon and are consistent with those from our first Phase 3 study. These combined results show that tedizolid phosphate represents a potential new therapy to treat severe skin infections with a once daily intravenous infusion or pill in fewer days than existing antibiotic medications. Combined with the results of our multiple other clinical and nonclinical studies, we believe that tedizolid may offer substantial benefits to patients and, potentially, payers and the healthcare system."  

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs